|
An end user reported an issue with a smartport 8f sl plastic non-filled det pu vi.A patient underwent internal jugular insertion of the port and received her first of four, chemotherapy treatments on (b)(6) 2026; consisting of docetaxel and cyclophosphamide.Palonosetron and pegfilgrastim were also delivered as supporting agents.Following the first chemotherapy treatment, the patient developed significant skin reactions and port site inflammation, leading to port removal on (b)(6) 2026, due to a suspected allergy.After port removal, the rash resolved and the patient tolerated the second cycle and g-csf injection without complications.Despite multiple good faith efforts, no further details have been obtained.
|